Mesoblast Limited MSB
ASX · Australia · Health Technology
AUD 2.07-0.04 (-1.90%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...
With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies, where the original builders still call key shots, can look appealing when capital is more expensive and decisions carry extra weight. This article highlights three such stocks from our founder focused screener. These three founder led Australian stocks are...
Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.